GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

GSK is opening the door to a new era in urinary ... plus a new launch for biologic depemokimab. All five should help the company achieve its recently increased 2031 sales goal of more than 40 ...

These include Blenrep for multiple myeloma and depemokimab for severe asthma. Overall, GSK ranks 6th on our list of the most undervalued biotech stocks to invest in. While we acknowledge the ...

GSK) is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK ranks 1st on our list of most undervalued healthcare stocks to ...

GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...